相关实验视频

Updated: Jun 11, 2025

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

肝移植中新出现的瘤征兆的免疫抑制方案:系统性审查和聚合分析

Roberta Angelico¹, Eliano Bonaccorsi Riani², Eleonora De Martin³

¹Department of Surgical Sciences, HPB and Transplant Unit, University of Rome Tor Vergata, Rome, Italy.

Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society

|September 30, 2024

概括

肝移植 (LT) 瘤学需要个性化的免疫抑制来防止瘤复发. 研究表明,在患有胆管癌和结肠直肠肝转移 (CRLM) 的患者中,应尽量减少塔克罗利,可能使用mTOR抑制剂.

科学领域:

肝病学肝病学是一种肝病学.
移植手术移植手术
在瘤学瘤学.

背景情况:

对于恶性疾病的肝脏移植 (LT) 正在增加.
优化免疫抑制是平衡移植存活和预防瘤复发的关键.
目前用于LT瘤的免疫抑制方案尚未标准化.

研究的目的:

系统地审查LT中针对特定癌症的免疫抑制协议:胆管癌,神经内分泌瘤 (NET),肝内皮血管内皮瘤和结肠直肠肝转移 (CRLM).
确定常见的做法,并评估它们与瘤学结果的关联.
建议在移植瘤学中对免疫抑制进行标准化报告.

主要方法:

从研究开始到2023年5月的研究的系统文献综述.
包括117项涉及6797名患有LT瘤迹象的患者的研究.
排除非人体研究,病例报告和小型病例系列 (n < 10).

主要成果:

只有41%的研究详细介绍了免疫抑制方案,20.8%报告了药物度最低点.
协议是异质的,在很大程度上反映了非瘤的LT实践.
结肠直肠肝转移 (CRLM) 病例显示,与哺乳动物目标拉巴胺抑制剂 (mTORi) 的塔克罗利斯最小化/撤销一致.
没有研究评估免疫抑制和瘤结局之间的直接联系.

结论:

有限的证据表明,使用最低的耐受性塔克罗利莫斯水平,密切监测瘤LT接受者.
将塔克罗利莫斯与mTOR抑制剂结合使用,以达到目标低度,可以使塔克罗利莫斯完全停用.
这种策略可能对高瘤复发风险的胆管癌和CRLM患者有益.

更多相关视频

In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients

In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients

Published on: August 12, 2017

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Published on: November 8, 2015

相关概念视频

Kidney Transplant I: Introduction

Kidney Transplant I: Introduction

A kidney transplant is a surgical approach that involves replacing a non-functioning kidney with a healthy one from a donor. This procedure is often a treatment option for end-stage renal disease (ESRD) patients. The method requires careful recipient selection, including evaluating various medical and psychosocial factors. These criteria vary between transplant centers but generally include assessments of the patient's overall health, adherence to medical recommendations, and lifestyle...

Tissue Transplantation

Tissue Transplantation

Tissue transplantation is a significant medical procedure involving the transfer of cells, tissues, or organs from a donor to a recipient, with the primary aim of restoring lost functions. This procedure is crucial in treating a broad spectrum of diseases, including kidney diseases, liver failure, heart disease, and certain types of cancers.
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...